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Summary. Protein kinase CK2 (previously known as 
casein kinase 11) is a protein serinelthreonine kinase that 
has been implicated in cell growth and proliferation. The 
focus of this review is on the apparent role of CK2 in 
cancer. Studies from severa1 laboratories have shown a 
dysregulated expression of the kinase in tumors. Nuclear 
matrix and chromatin appear to be key sites for signaling 
of the CK2 activity in relation to cell growth. Severa1 
types of growth stimuli produce a common downstream 
response in CK2 by enhancing its nuclear shuttling. The 
neoplastic change is also associated with changes in 
intracellular localization of the kinase so that a higher 
nuclear localization is obsewed in tumor cells compared 
with normal cells. Experimental studies suggest that 
dysregulated expression of the a subunit of CK2 imparts 
an oncogenic potential in the cells such that in 
cooperation with certain oncogenes it produces a 
profound enhancement of the tumor phenotype. Recent 
studies have provided evidence that overexpression of 
CK2 in tumor cells is not simply a reflection of tumor 
cell proliferation alone but additionally may reflect the 
pathobiological characteristics of the tumor. Of 
considerable interest is the possibility that CK2 
dysregulation in tumors may influence the apoptotic 
activity in those cells. Approaches to interfering with the 
CK2 signal may provide a useful means for inducing 
tumor cell death. 
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lntroduction 
The protein kinase commonly identified as casein 
kinase 2, and now generaliy referred to by the preferred 
name of CK2, has been known for almost half a century 
though not by this specific name. Over the past 25 years, 
CK2 has continued to gain increasing attention for its 
potential involvement in a variety of cellular processes, 
and especially for its role in regulation of cell growth 
and proliferation. Much progress has been made on the 
analysis of its structure and properties, and severa1 
recent reviews provide a broad overview of the general 
characteristics and functions of CK2 (Tuazon and 
Traugh, 1991; Ahmed, 1994, 1999; Pinna and Meggio, 
1997; Allende and Allende, 1998; Guerra and Issinger, 
1999; Guerra et al., 1999a). In the present overview, we 
aim to focus largely on the potential role of CK2 in the 
process of neoplasia. 
Properties and general features of CK2 activity 
Protein kinase CK2 is a highly conserved enzyme 
having extensive homology across species and almost 
complete structural identity among the mammalian 
tissues. The kinase consists of two catalytic subunits (a, 
a ' )  and the regulatory subunit (B) existing as a2P2, 
aaYB2, or configurations, such that the a subunits 
are linked through the B subunits. The protein kinase is 
localized in the cytoplasmic and nuclear compartments. 
Within the nucleus, chromatin and nuclear matrix appear 
to be important loci of its signaling in response to 
various stimuli (Ahmed, 1999). Further, it appears that 
certain cysteine residues in the B subunit may play a role 
in anchoring the kinase to the nuclear structures (Zhang 
et al., 1998). 
A large number of cellular (cytoplasmic as well as 
nuclear) proteins have been suggested as putative 
substrates of CK2 which points to its multiple functional 
activities. CK2 is a protein serinelthreonine kinase which 
is active generally towards acidic protein substrates with 
the general consensus sequence of S/TXXD/E. The 
reader is referred to recent detailed compilations of the 
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currently known protein substrates of CK2 (Allende and 
Allende, 1998; Pinna and Meggio, 1997; Guerra et al., 
1999a; Guerra and Issinger, 1999; Blanquet, 2000); for 
the reader's convenience, here we have provided a 
summary of this information in Table 1 based on a 
functional classification of some of the protein substrates 
(the original references can be found in these review 
articles). It is noteworthy that many of the putative 
substrates are related to growth and proliferation 
activities of the cell, especially those associated with the 
nucleus. The critica1 nature of the role of CK2 in cell 
biology is further underscored by the observation that it 
also appears to be essential for cell survival 
(Padmanabha et al., 1990). 
The cellular regulation of CK2 remains poorly 
defined since it is not clear how its activity is regulated 
in response to various stimuli. The crystal structure of 
the a subunit (of maize CK2) has provided an 
explanation of the possible intrinsic activation of the 
catalytic activity (Guerra and Issinger, 1999; Guerra et 
al., 1999a). Other aspects of the CK2 regulation in the 
cell have also been considered, and may be pertinent to 
its biological activity. For example, it has been suggested 
that the cataiytic a subunit may not be available because 
of its being complexed with other entities in the cell 
(Stigare et al., 1993; Guerra and Issinger, 1998; Guerra 
et al., 1999b). It has been proposed that interaction of the 
individual subunits of the kinase with other proteins may 
serve as a functional regulatory mechanism for its 
signaling (Allende and Allende, 1998). Likewise, 
specific modulations in various locales via translocation 
of the kinase (e.g., in the nuclear components) in 
response to certain stimuli which regulate growth may 
represent a mode of regulation of the functional activity 
of the enzyme (Tawfic et al., 1996; Ahmed, 1999). It is 
conceivable that al1 these factors play a role in 
controlling the functional kinase activity at specific loci 
in response to various stimuli, as discussed subsequently. 
Dysregulation of CK2 in neoplasia 
It has been noted in severa1 studies that CK2 is 
markedly elevated in hematopoietic and solid tumors 
(Issinger and Boldyreff, 1992; Ahmed, 1994). Among 
the solid tumors in which increased levels and activity of 
CK2 have been documented are tumors of the prostate 
(Rayan et al., 1985; Yenice et al., 1994), kidney 
(Münstermann et al., 1990; Stalter et al., 1994), colon 
(Seitz et al., 1989), chemical carcinogenesis in liver 
(Ahmed, 1974), lung (Daya-Makin et al., 1994), and 
squamous cell carcinoma of the head and neck (Gapany 
et al., 1995; Faust et al., 1996). Likewise, increased CK2 
has been noted in hematopoietic malignancies such as 
leukemia and lymphomas (Phan-Dinh-Tuy et al., 1985; 
Wang et al., 1995; Landesman-Bollag et al., 1998; Roig 
et al., 1999). Summarized in Table 2 are these 
observations on dysregulation of CK2 in tumors. 
As noted in these various examples, the 
enhancement in CK2 activity (measured by biochemicai 
analysis on tissue extracts or specific isolated cell 
Table 1. A few of the protein substrates of CK2 that are potentially 
involved in the process of oncogenesis* . 
FUNCTIONAL GROUP SUBSTRATES 
Proteins involved in nucleic 
acid synthesis and repair 
Transcription factors 
including oncogenes and 
tumor suppressor genes 
Factors involved in protein 
synthesis 
Proteins involved in signal 
transduction 
Viral proteins 
DNA ligase, DNA topoisomerases I 
and II, RNA polymerases I and II, 
BRCAl gene product 
c-myc, N-myc, C-jun, p53, Rb, 
androgen receptor, serum response 
factor, mdm2 
p34cdc-2, Protein kinase C, Protein 
kinase A - regulatory subunit, lnsulin 
receptor, IGF-ll receptor, Protein 
phosphatase 2A 
Human papilloma: E7, SV40: large T, 
Polyoma: VP1, HIV: Vpu, Herpes 
simplex: VP22, VP16, protein a22, R1 
subunit, EBV: ZEBRA protein, EBNA-2 
*: for specific references, see Pinna and Meggio, 1997; Guerra and 
Issinger, 1999; Guerra et al., 1 W a ;  Blanquet, 2000. 
Table 2. Observations on dysregulated expression of CK2 in tumors. 
TUMOR TYPE INCREASE IN CK2 METHODS OF DETECTION REFERENCE 
ENZYME ACTlVPl 
Colorectal 
adenocarcinoma 
Breast carcinoma 
Renal cell carcinoma 
Non-small cell carcinoma 
of lung 
Acute myeloid leukemia 
and chronic myeloid leukemia 
in acute blast crisis 
Prostatic adenocarcinoma 
Squamous cell carcinoma 
of the head and neck ISCCHN) 
Up to 8-fold Protein leve1 by immunoblot and ac t i v i  assays; 
immunohistochemistry 
lmmunohistochemistry 
Protein level by immunoblot and activii assays 
Activiiy assay 
3- to 5-fold Acüvity assay and immunohistochemistry 
2- to bfold Activiiy assay and immunohistochemistry 
Munstermann et al., 1990 
Seitz et al., 1989 
Munstermann et al., 1990 
Stalter et al., 1994 
Daya-Makin et al., 1994 
Phan-Dinh-Tuy et al., 1985 
Yenice et al., 1994 
Gapany et al., 1995; 
Faust et al.. 1996. 1999a 
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fractions) was obsewed to be in the range of 2- to 8-fold 
compared with the corresponding normal controls. 
However, it must be emphasized that these values are 
based on crude cellular materials from whole tissues 
(which rnay consist of numerous cell types, etc.) and as 
such rnay not reflect the precise nature of the 
dysregulation in the affected cells. However, when the 
biochemical and immunohistochemical analyses on the 
same tumor sample are compared a reasonable 
correlation of the two is noted. In general, these results 
can be taken to indicate a general relation of the altered 
CK2 to the neoplastic state. A careful biochemical 
analysis of CK2 in the well-defined tumor specimens 
can lead to additional general conclusion on the 
pathological status, as discussed subsequently (Faust et 
al., 1999a). The observations that CK2 is elevated in 
cancer cells as well as normal proliferating cells rnay 
suggest that the kinase is simply a proliferation marker. 
However, as discussed subsequently, recent immuno- 
histochemical studies using anti-CK2.a antibody and the 
commonly employed proliferation marker antibody Ki- 
67 have revealed that this conclusion rnay not be 
appropriate to fully represent the biological function of 
CK2 (Faust et al., 1999a). Thus, we suggest that careful 
immunohistochemical analysis of CK2 expression in 
tumor cells rnay yield important information in 
evaluation of its potential role in the pathological 
manifestations of the dysregulated CK2. 
The change in the CK2 enzyme expression in tumor 
cells does not appear to be related to an alteration in the 
level of the CK2 message at the transcriptional level, as 
noted by us from studies of the RNA expression in 
prostate cancer and squamous cell carcinoma of the head 
and neck (Table 3). The mRNA expression levels for the 
a and B subunits of CK2 were determined in prostate 
and SCCHN samples by employing the slot blot 
technique followed by densitometric analysis of the 
autoradiograms. The results in Table 3 do not reflect a 
significant change in the expression of CK2 mRNA in 
prostate cancer or SCCHN specimens compared with the 
corresponding normal tissues. This suggests that the 
dysregulation of CK2 obsewed in cancer rnay occur at 
the post-transcriptional level. That no mutations in 
Table 3. CK2 mRNA levels in normal and neoplastic prostate and 
oropharyngeal tissue specimens*. 
Human Prostate 
Normal 
BPH 
Tumor 
SCCHN 
Normal 
Metastatic lymph node 
Pnmary tumor 
*: mRNA expression levels for CK2 subunits are presented as relative 
values per DNA equivalent in the sample (based on 4-8 samples in each 
case). 
CK2a gene in neoplasia have been described supports 
this notion. 
CK2 in tumor pathobiology 
The ubiquitous dysregulation of CK2 in tumors 
would suggest that it reflects diverse pathobiological 
characteristics of tumor cells. Studies dealing with 
various aspects of the dysregulated expression in tumors 
and their implications in tumor cell biology are 
discussed in the following. 
Nature of CK2 expression in tumors 
Based on the above discussion, it would be of 
interest to determine whether the degree of dysregulation 
in CK2 activity in the tumor cells, compared with the 
corresponding normal cells, reflects the severity of the 
disease. There is a paucity of information on this subject. 
However, it was recently documented that the level of 
CK2 in the head and neck tumor cells correlated with the 
tumor grade, stage, and clinical outcome (Gapany et al., 
1995). Concordant with these studies was the 
observation suggesting an association of CK2 in the 
chromatin of head and neck tumors with malignant 
transformation (Faust et al., 1996). For prostate cancer 
also, the CK2 activity in the tumor showed a correlation 
with Gleason grade (Yenice et al., 1994). Taken together, 
these studies point to the possible involvement of CK2 
in many aspects of tumor biology such as differentiation, 
invasion, metastasis, and response to therapy. 
Immunohistochemical analysis of CK2 in tumors 
(such as prostatic adenocarcinoma and SCCHN) reveals 
interesting features of its localization in tumor cells as 
well as in cells (e.g., tumor infiltrating lymphocytes) 
invading the tumors (Yenice et al., 1994; Faust et al. 
1999a). It appears that the distribution of CK2 within the 
tumor cells in the tissue is not uniform. In general, the 
tumor cells at the periphery (or the infiltrating edge) of 
the tumor show a higher concentration of CK2 than in 
tumor cells located more centrally. This rnay be pertinent 
to the consideration that the infiltrating edge of tumors 
has the capacity to secrete soluble factors that faciIitate 
the process of local invasion of surrounding stroma and 
basement membranes. Biochemical and immunohisto- 
chemical studies have shown that intracellular elevated 
levels of CK2 are differentially distributed in various 
compartments of the cell and rnay be distinct from that 
obsewed for the normal cells. In tumor cells compared 
with normal, CK2 is localized preferentially in the 
nuclear compartment (Yenice et al., 1994; Faust et al., 
1999a). The results of the CK2 activity measurements by 
biochemical methods accord with those obtained by 
employing immunohistochemical analysis of the same 
tumor specimens although additional features of CK2 
differential cellular localization were noted with the use 
of immunohistochemistry (Faust et al., 1999a). By 
employing the antibodies to the a subunit of CK2 (anti- 
CK2-a antibody), we found that the catalytic subunit 
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was localized predominantly to the nuclei in tumor cells 
but that not al1 tumor cells were stained with the same 
intensity with the anti-CK2-a antibody. Interestingly, the 
CK2-a staining pattern in benign squamous mucosa of 
head and neck was distinct from that observed in its 
malignant counterpart (Faust et al., 1999a). The chiefly 
nuclear distribution of CK2-a immunostaining found 
consistently in these tumor cells (and tumor-infiltrating 
lymphocytes) contrasted with a relatively more 
predominant cytosolic staining pattern demonstrated by 
celiular constituents of normal oropharyngeal mucosa. In 
general, the proliferating front of squamous infiltration 
was strongly positive for CK2-a staining. This is 
analogous to the previous observations on prostate and 
colon cancers (Seitz et al., 1989; Yenice et al., 1994). 
Further, it was noted that nuclei of the infiltrating 
lymphocytes in the squamous cell carcinoma specimen 
also stained intensely for CK2-a; the significance of this 
observation is not entirely clear but it may be related to 
increase in secretory/proliferative or anti-apoptotic 
activities of lymphocytes within the tumor cells. At still 
higher magnification, it was observed that the nuclear 
staining of the squamous cell carcinoma of the head and 
neck cells exhibited a punctate pattern for CK2-a 
staining. This suggests non-uniform distribution of CK2 
in the nucleus with foca1 collections. This is consistent 
with the association of CK2 with chromatin and nuclear 
matrix structures, as documented by us in several studies 
(Ahmed and Goueli, 1987; Ahmed et al., 1993; Faust et 
al., 1996; Tawfic et al, 1996; Guo et al., 1998; Ahmed, 
1999; Yu et al., 1999). Of note, desmoplastic fibroblasts 
that were found in the stroma of the tumor sections 
showed significant staining of the cytoplasm as well as 
nucleus. This may accord with the proliferative activity 
of desmoplastic stroma around the tumor. In summary, 
irnrnunohistochemical studies showed enhanced, mostly 
nuclear, staining in tumor cells, tumor-infiltrating 
lymphocytes, and surrounding desmoplastic stroma 
compared to normal cellular counterparts. In addition, 
the differential high-intensity staining of tumor cells at 
the periphery of the tumor may reflect the additional 
biological activities assigned to tumor cells at this 
location as mentioned above. In other work, we have 
provided evidence on the growth stimulus mediated 
signaling of CK2 to chromatin and nuclear matrix 
(Ahmed, 1999). The immunohistochemical observations 
on the tumor specimens (Faust et al., 1999a) further 
point to the important role of these nuclear structures in 
dysregulated CK2 signaling. 
Other studies on immunoblots of certain tumor 
derived samples (e.g., from acute myeloid leukemia, 
HL-60, and mouse Krebs ascites cells) have 
demonstrated multiple forms of the a subunit of CK2 
(Guerra and Issinger, 1999; Roig et al., 1999) which 
have been suggested to arise from their proteolytic 
degradation (Roig et al., 1999). Of interest are also the 
observations which indicate asymmetric expression of 
the a and B subunits in certain tumors. For example, in 
renal clear cell carcinomas it was noted that the ratio of 
the a subunit in the tumor versus normal specimen was 
1.5810.47 whereas that for the B subunit was 2.6521.1 
implying that in tumors altered expression of the 
subunits may have some pathobiological relevance 
(Stalter et al., 1994). A careful analysis of specific 
tumors in relation to their pathological characteristics 
compared with the corresponding normal specimens is 
warranted to generate additional data along these lines 
which might indicate the role of this disturbance in the 
pathogenesis of the tumor. 
CK2 reflects not only proliferation but also 
pathobiological character of the cells 
The association of CK2 with rapid proliferation 
(normal as well as abnormal) has prompted the general 
notion that it might simply reflect the growth status of 
the cells. However, a high level of cellular CK2 does not 
simply correlate with the proliferative activity as 
indicated, for example, by the high level of CK2 in brain 
(see e.g., Guerra and Issinger, 1999). Given that CK2 
has an apparent role in a rather wide range of cellular 
activities, including cell growth, it would seem that the 
actual level of CK2 in a given cell type may be dictated 
by the functional needs of the cell. Thus, the extent of 
the CK2 activity alone may not be informative; rather, 
the change from the normal for the particular cell type 
may be a critica1 determinant for an alteration in the 
biological response of the cells. As discussed 
subsequently, support for this concept comes from the 
experimental studies which suggest an oncogenic 
potential of even a small dysregulation of CK2 in the 
cell (Landesman-Bollag et al., 1998). In this regard, it is 
pertinent that the effects of overexpression of CK2 on 
cell proliferation can yield apparently contradictory 
results. It was observed that overexpression of CK2-a 
and CK2-a' can enhance proliferation in fibroblasts 
(Orlandini et al., 1998), whereas another report has 
suggested that overexpression of CK2 caused a 
reduction in proliferation especially when enzyme 
containing the a' subunit was compared with that 
containing the a subunit (Vilk et al., 1999). The reasons 
for this discrepancy are not entirely clear but it would 
appear that the type of cells used for overexpression 
studies may influence the results on the effects of 
overexpression of CK2. 
To address the question whether CK2 expression is 
simply a reflection of proliferation activity, we compared 
the immunohistochemical profiles of the same tissue 
sections by employing the anti-CK2-a antibody and the 
antibody for the commonly utilized proliferation-marker 
Ki-67 (Faust et al., 1999a). Ki-67 is a nuclear antigen 
whose expression is an absolute requirement for 
progression through the cell-division cycle (Scholzen 
and Gerdes, 2000). Our results clearly indicated distinct 
patterns of CK2-a and Ki-67 immunostaining in the 
same tissue sections (Fig. 1). As expected, immuno- 
staining for Ki-67 was most intense at the mitotically 
active areas of the tumor which contrasted with CK2-a 
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immunoreactivity that was found to be positive to 
varying extents throughout the same tumor in addition to 
the enhanced staining at the leading edge of the tumor as 
mentioned earlier. In general, it appeared that anti-CK2- 
a immunostaining was particularly remarkable in 
moderately to poorly differentiated carcinomas, whereas 
in well-differentiated carcinomas there was a relatively 
decreased CK2-a immunoreactivity in the central 
keratinizing zone. These observations clearly indicate 
that CK2 cannot be regarded strictly as a proliferation 
marker per se. Rather, it appears that it does associate 
with proliferation but more importantly its activity may 
relate to the pathobiological characteristics of the tumor 
cells such as the state of differentiation, etc. In this 
regard, it should be noted that our data on the CK2 in 
squamous cell carcinoma of the head and neck 
demonstrated a highly significant Kaplan-Meier 
cumulative survival analysis. It was observed that 
survival in the high-CK2 activity patient group was 
greatly reduced suggesting the potential usefulness of 
CK2 as a prognostic indicator in certain malignancies 
(Gapany et al., 1995). 
Oncogenic potential of CK2 and modes of CK2 
function 
Transgenic models of CK2 function in tumor growth 
Various lines of evidence suggest that dysregulated 
presence of CK2 may augment the oncogenic potential 
in the cell by cooperating with other factors (Xu et al., 
1999). A more direct evidence in support of the potential 
oncogenic role of CK2 comes from the studies on the 
incidence of lymphoma in mice carrying CK2-a 
transgene (see e.g., Xu et al., 1999). Based on the 
obsewation that in cattle infected with Theileria parva 
there was a marked upregulation of CK2 associated with 
incidence of pseudo-leukemia in infected cells, studies 
were undertaken to demonstrate that ectopic 
coexpression of CK2-a along with c-myc in transgenic 
mouse model resulted in a large increase in the incidence 
of lymphoma (Seldin and Leder, 1995). Further studies 
along these lines demonstrated similar responses to 
transgenic co-expression of CK2-a with Tal-1 or altered 
p53 expression (Kelliher et al., 1996; Landesman-Bollag 
et al., 1998). In these studies, ectopic expression of the 
CK2-a transgene was not extensive such that it was not 
detectable by simple means. Thus, the results suggest 
that even a very mild dysregulation in the 'intrinsic' 
leve1 of CK2 in a given cell could contribute toward 
significant pathological consequences. 
Of considerable interest are also severa1 recent 
reports implicating phosphorylation of viral proteins by 
CK2 in pathological processes. Virally transformed cells 
demonstrate higher levels of CK2 (Brunati et al., 1986). 
It now appears that many of the viral proteins are 
phosphorylated by CK2; at least 13 different viruses 
have been found to contain CK2-mediated 
phosphorylated proteins, and the number of viral 
proteins which are candidates for phosphorylation by 
CK2 seems to continue to increase (for a review, see 
e.g., Guerra and Issinger, 1999). These viral proteins 
phosphorylated by CK2 appear to play multiple roles, 
which strongly suggests a role of CK2 in virally 
mediated pathologies including cancers. 
CK2 and apoptosis 
Oncogenic proteins might influence the growth by 
stimulating proliferation andlor by an effect on the 
apoptotic activity in the cell. Our studies on the 
androgenic regulation of the prostate had indicated that 
CK2 might be involved in both of these activities. For 
exarnple, androgen deprivation which results in receptor- 
mediated apoptosis in rat ventral prostate results in a 
rapid loss of CK2 from chromatin and NM and that this 
event temporally precedes the appearance of apoptosis 
(Ahmed et al., 1993; Tawfic and Ahmed, 1994a,b; 
Tawfic et al., 1994, 1995; Guo et al., 1998; Ahmed, 
1999). Of equal importance, the translocation of CK2 
from the cytoplasm to the nuclear compartments occurs 
very rapidly (during the pre-replicative phase) on 
induction of growth by androgenic stimulus in the 
animal. Thus, the receptor-mediated loss of CK2 from 
Flg. 1. lmrnunohistochemical staining for CK2-a and Ki-67 in the carne tumor specimen. A. Paítern of Ki-67 staining. B. lmmunostaining paítern of 
CK2-a. C. Negative control. All sections are lightly counter-stained with hematoxylin. For further details, see text. (Reproduced from Faust et al.. 1999a, 
with perrnission). x 100 
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the nucleus can be equated with cessation of cell growth 
activity as well as induction of apoptosis, whereas the 
reverse would imply involvement of CK2 in stimulation 
of growth and inhibition of apoptotic activity. To address 
the role of CK2 in apoptosis more directly, we examined 
the effects of chemical-mediated apoptosis on nuclear 
dynamics of CK2. We observed that in severa1 cancer cell 
lines, treatment with etoposide resulted in induction of 
apoptosis; however, there was a marked concomitant 
increase in the NM-associated CK2. This appeared to 
result in part from its translocation from the cytoplasm 
suggesting a possible protective effect of CK2 in 
response to etoposide-mediated cell death. In support of 
this notion we found that forced transient overexpression 
of CK2-a and CK2-a8 resulted in significant protection 
of the cells against etoposide mediated apoptosis. The 
critica1 role of the a subunit of CK2 was indicated by the 
observation that overexpression of CK2-B did not evoke 
such a response (Guo et al., 2000a,b; Yu et al., 2000). 
Diethylstilbestrol @ES) another chemical agent which is 
known to induce apoptosis in prostate cancer cells 
(Robertson et al., 1996), gave similar results as etoposide 
(Yu et al., 2000). Thus, our data provide evidence for the 
first time in support of the view that CK2 has the ability 
to exert an effect on the apoptotic activity in cells. This 
observation has strong implications for a role of this 
kinase in neoplasia. It is noteworthy that treatment of 
cancer cells with antisense oligonucleotides against the a 
subunit of CK2 produces a strong inhibition of cell 
growth which appears to be through induction of 
apoptosis (Faust et al., 2000). Interestingly, the antisense 
to CK2-a produced nearly a 100% growth inhibition and 
cell death at concentrations which reduced the CK2 
activity by 40%, implying that even a modest alteration 
(reduction) in the CK2 leve1 intrinsic to the tumor cells 
might compromise viability of tumor cells under these 
conditions. This is the first study which employed 
antisense to CK2-a as an anticancer modality suggesting 
a potential of using this approach to anticancer therapies. 
Possible mechanisms of CK2 regulation and involvement 
in tumors 
Based on the above discussion, there seems no doubt 
that CK2 plays a significant role in the process of 
oncogenesis. Therefore, it would be important to define 
the mechanism(s) of its involvement in this process. This 
is a problematic question at the present time since the 
mechanism(s) by which CK2 is regulated in the cell 
even under normal growth has not been fully defined. As 
this field progresses, it should find application in 
yielding insights into the mechanism(s) that are involved 
in the normal and cancerous cell growth. Nonetheless, 
sufficient information on this subject has emerged to 
enable us to speculate and hypothesize. 
The primary issue regarding the regulation of CK2 
in vivo remains unresolved. Various studies have 
indicated that the catalytic subunit of the kinase is 
intrinsically active. Certainly, recent studies on the 
crystal structure of CK2-a have provided an explanation 
why the catalytic subunit of CK2 could remain 
constitutively active (Guerra and Issinger, 1999; Guerra 
et al., 1999a), and this rnay account for why CK2 
isolated from cells always appears to be active. 
However, since CK2 is involved in many cellular 
functions including control of cell growth and 
proliferation which are unlikely to be random processes, 
this raises the problematic issue of the response to 
various stimuli which affect the functional activity of the 
kinase in various intracellular locales. In this context, a 
number of possibilities have emerged from studies in 
various laboratories which hint at severa1 potential subtle 
modes of the functional regulation of CK2 in the cell. 
Evidence has been provided in support of the notion 
that the a and 8 subunits of CK2 in the cell rnay not 
always be fully complexed, and rnay exist as free 
subunits or in complex with other proteins (Stigare et al., 
1993; Guerra et al., 1999b; Guerra and Issinger, 1998). 
Among the latter are included key molecules such as 
nucleolin, B23, topoisomerases, RNA polymerases, p53, 
MDM2, p2lwafllcip1, p34cdc, Myc/Max, tubulin, etc. 
Phosphorylation andlor association of these molecules 
with subunits of CK2 often reveals complex interactions 
and consequences, including a potential role in neoplasia 
(see e.g., Bousset et al., 1993; Tawfic et al., 1994, 1995; 
Filhol et al., 1996; Gotz et al., 1996, 1999a,b, 2000; 
Bosc et al., 1999; Egyhazi et al., 1999; Faust et al., 
1999b; Ghavidel et al., 1999; Leroy et al., 1999; 
McKendrick et al., 1999). Further, the ability to 
independently interact with a rather large number of 
proteins (or partners) (Grein et al., 1999; Guerra and 
Issinger, 1999; Kusk et al., 1999) would suggest that 
activity of CK2 rnay be modulated by such interactions 
in the cell, thus creating a subtle means of regulating 
functional cellular activity of the kinase under various 
conditions. It has been proposed that there might be 
certain "wild-card" proteins which could serve as 
switches by interacting with CK2 subunits (Allende and 
Allende, 1998). In this regard, the a subunit of CK2 has 
been shown to be a target for the Abl and Bcr-Abl 
tyrosine kinases implying that CK2 rnay represent a 
mediator for Bcr-Abl (Hériché and Chambaz, 1998). 
Similarly, CD5 which is a T-cell marker and is expressed 
aberrantly on B lymphocytes of chronic lymphocytic 
leukemia was found to directly interact and enhance 
CK2 activity (Raman et al., 1998). Another example 
relates to the BRCAl gene which encodes a complex 
protein that appears to be involved in some aspects of 
DNA repair. Mutations in BRCAl gene on chromosome 
17p account for many cases of familia1 breast carcinoma 
and predisposition to ovarian carcinoma. This protein 
has been found to bind to CK2 which phosphorylates it. 
The interaction is reduced in vitro when BRCAl 
fragment bearing a disease-associated mutation was used 
implicating CK2 as a potential mediator of BRCAl 
activity (O'Bnen et al., 1999). 
As we have proposed, a mode of cellular regulation 
of CK2 rnay relate to the potential of its dynamic 
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shuttling to different compartments in the cell in 
response to various stimuli (Ahmed, 1999). This 
hypothesis is based on our observations that CK2 
undergoes very rapid modulations in its association with 
chromatin and nuclear matrix with altered status of 
growth stimuli, including hormones and growth factors 
(Ahmed et al., 1993; Tawfic and Ahmed, 1994a,b; Guo 
et al., 1998, 1999a,b; Ahmed, 1999; Yu et al., 1999). In 
addition, it seems that intranuclear activities (such as 
transcription and DNA synthesis) that are associated 
with displacement of histone proteins qualitatively and 
quantitatively affect CK2 activity focally in these 
locations which rnay afford yet another subtle means of 
CK2 regulation and its involvement in these essential 
activities (Ahmed, 1999; Tawfic et al., 1999). We have 
recently observed specific modulation of nuclear matrix- 
associated CK2 during cell cycle progression (Wang, Yu, 
Davis and Ahmed, unpublished data). These 
observations accord with previously reported cell cycle 
related changes in nuclear CK2 (Marshak and Russo, 
1994; Pinna and Meggio, 1997; Bosc et al., 1997). 
Further work is needed to understand the process of 
spatio-temporal regulation of CK2 in the nucleus in 
response to growth stimuli and in neoplasia. 
Given the present state of knowledge on CK2 
regulation in the cell, one can only speculate on the 
various means by which it is involved in the process of 
oncogenesis. First, based on the studies employing 
transgenic expression of CK2 (Xu et al., 1999), it would 
seem that the absolute amount of CK2 in a given cell 
under normal conditions would be relatively constant 
and that even a small deviation from this (e.g., by 
overexpression) could disturb the system in a way as to 
make it highly susceptible to the presence of other 
oncogenic stimuli (Seldin and Leder, 1995; Landesman- 
Bollag et al., 1998). Likewise, the shuttling of the kinase 
to distinct sites can be a feature of importance to the 
cancer phenotype as observed by immunohistochemical 
analysis which showed a more diffuse presence of CK2 
in the cytoplasm of benign or normal specimens while in 
the cancer specimen an intense localization in the 
nucleus was the more obvious feature (Yenice et al., 
1994; Faust et al., 1999). This rnay not only influence 
the activities associated with growth and proliferation 
but also those associated with regulation of apoptotic 
activity in the cancer cells (Guo et al., 2000a,b; Yu et al., 
2000). The latter feature of CK2 function rnay be 
particularly important in regard to the process of 
neoplasia as it rnay come into play when the cell 
encounters dysregulation in the intrinsic leve1 of CK2. 
Involvement of CK2 in neoplasia by virtue of its 
activity in the phosphorylation of certain proteins also 
remains a major candidate for this role. As stated earlier, 
the list of the putative substrates for CK2 is quite large 
including a variety of nuclear proteins and oncogenes 
which infiuence cell cycle and proliferation (for general 
reviews see e.g., Tuazon and Traugh, 1991; Ahmed, 
1994, 1999; Pinna and Meggio, 1997; Guerra and 
Issinger, 1999; Blanquet, 2000). Complex interactions of 
CK2 and p53 are further highlighted by observations that 
cell type specific p53 transactivation rnay produce 
varying degrees of alteration of the promoters for 
MDM2, cyclin G, Bax and Fos (Schuster et' al., 1999). 
Also germane to these considerations are our studies 
which have suggested that severa1 proteins associated 
with the nuclear matrix and chromatin are 
phosphorylated by CK2 (see e.g., Ahmed, 1999). The 
involvement of CK2 in the phosphorylation of 
chromatin-associated proteins in relation to 
transcriptional activity in the nucleosomes indicates a 
number of proteins that are candidates for 
phosphorylation by CK2 under different conditions. Of 
interest was the observation that phosphorylation of 
certain proteins was noted only in the transcriptionally- 
active nucleosomes and of some others only in the 
transcriptionally-inactive nucleosomes (Guo et al., 1998. 
1999a). 
Concluding remarks 
Our recent proposal on a role of CK2 at the interface 
of the nuclear matrix and chromatin structures rnay be of 
interest as it suggests a paradigm for involvement of 
phosphorylation of nuclear matrix and chromatin 
proteins in a spatio-temporal manner thereby influencing 
the status of chromatin with respect to its transcriptional 
activity (Ahmed, 1999). Such proteins rnay represent 
transcription factors and other regulatory molecules 
involved in the control of growth related activity in the 
cell (Guo et al., 1998, 1999a,b; Ahmed, 1999). The 
modulations in signaling of CK2 in response to diverse 
stimuli could reflect its key function in the 
pathobiological features of cancer cell growth (Ahmed, 
1999; Guo et al., 1999b). The involvement of structural 
constraints in the biological functions such as cell 
growth and proliferation continues to be recognized (for 
a detailed review, see e.g., Stein et al., 2000). Given that 
nuclear structural alterations represent a hallmark of 
cancerous transformation, it would be important to 
identify and define the role of the factors relating to the 
functionality of the structures such as chromatin and 
nuclear matrix and what factors contribute to their 
altered state. We propose that CK2 is one such factor 
which interacts with the chromatin and nuclear matrix, 
and merits further consideration from these points of 
view, especially relating to neoplastic transformation. 
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